8月1日，神经分泌生物科学盘中下跌9.92%，报167.10美元/股，成交额3.76亿美元。
消息面上，公司于7月30日盘后公布Q2财报，调整后每股收益2.85美元，同比增长72.73%，远超市场一致预期的1.34美元，超预期幅度达112.69%；营收9.59亿美元，同比增长39.4%，超出预期的8.83亿美元。公司同时将核心产品Ingrezza全年净销售额指引上调至28.25亿至28.75亿美元。尽管业绩全面超预期且上调指引，股价仍出现大幅回调。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.